KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Taxes (2017 - 2020)

Historic Current Taxes for Aquestive Therapeutics (AQST) over the last 4 years, with Q4 2020 value amounting to $316000.0.

  • Aquestive Therapeutics' Current Taxes rose 533.33% to $316000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $316000.0, marking a year-over-year increase of 533.33%. This contributed to the annual value of $316000.0 for FY2020, which is 533.33% up from last year.
  • As of Q4 2020, Aquestive Therapeutics' Current Taxes stood at $316000.0, which was up 533.33% from $370000.0 recorded in Q1 2020.
  • Over the past 5 years, Aquestive Therapeutics' Current Taxes peaked at $388000.0 during Q4 2018, and registered a low of $176000.0 during Q2 2019.
  • Over the past 4 years, Aquestive Therapeutics' median Current Taxes value was $327000.0 (recorded in 2018), while the average stood at $312500.0.
  • As far as peak fluctuations go, Aquestive Therapeutics' Current Taxes crashed by 3307.98% in 2019, and later skyrocketed by 533.33% in 2020.
  • Over the past 4 years, Aquestive Therapeutics' Current Taxes (Quarter) stood at $372000.0 in 2017, then increased by 4.3% to $388000.0 in 2018, then dropped by 22.68% to $300000.0 in 2019, then grew by 5.33% to $316000.0 in 2020.
  • Its Current Taxes stands at $316000.0 for Q4 2020, versus $370000.0 for Q1 2020 and $300000.0 for Q4 2019.